[go: up one dir, main page]

NO20092535L - Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol - Google Patents

Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol

Info

Publication number
NO20092535L
NO20092535L NO20092535A NO20092535A NO20092535L NO 20092535 L NO20092535 L NO 20092535L NO 20092535 A NO20092535 A NO 20092535A NO 20092535 A NO20092535 A NO 20092535A NO 20092535 L NO20092535 L NO 20092535L
Authority
NO
Norway
Prior art keywords
alpha
beta
naphthalenyl
dimethylamino
bromo
Prior art date
Application number
NO20092535A
Other languages
English (en)
Other versions
NO342773B1 (no
Inventor
Sigrid Carl Maria Stokbroekx
Yolande Lydia Lang
Jean Francois Alexandre Lucas Hegyi
Wim Albert Alex Aelterman
Carina Leys
Peter Jozef Maria Van Remoortere
Anne Faure
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092535(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20092535L publication Critical patent/NO20092535L/no
Publication of NO342773B1 publication Critical patent/NO342773B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen angår fumaratsaltet av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol, farmasøytiske sammensetninger omfattende som aktiv ingrediens nevnte salt og fremgangsmåter for deres fremstilling.
NO20092535A 2006-12-05 2009-07-06 Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol NO342773B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05
PCT/EP2007/063186 WO2008068231A1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (2)

Publication Number Publication Date
NO20092535L true NO20092535L (no) 2009-08-06
NO342773B1 NO342773B1 (no) 2018-08-06

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092535A NO342773B1 (no) 2006-12-05 2009-07-06 Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol

Country Status (34)

Country Link
US (1) US8546428B2 (no)
EP (1) EP2086940B1 (no)
JP (2) JP2010511663A (no)
KR (1) KR101514700B1 (no)
CN (2) CN105012303A (no)
AP (1) AP2498A (no)
AR (1) AR064149A1 (no)
AU (1) AU2007328945B2 (no)
BR (1) BRPI0719693A2 (no)
CA (1) CA2668512C (no)
CL (1) CL2007003472A1 (no)
CY (1) CY1113594T1 (no)
DK (1) DK2086940T3 (no)
EA (1) EA017091B9 (no)
ES (1) ES2387923T3 (no)
HK (1) HK1214513A1 (no)
HR (1) HRP20120639T1 (no)
IL (1) IL199077A (no)
JO (1) JO2973B1 (no)
ME (1) ME01456B (no)
MX (1) MX2009005909A (no)
MY (1) MY148844A (no)
NO (1) NO342773B1 (no)
NZ (1) NZ576485A (no)
PE (1) PE20081350A1 (no)
PL (1) PL2086940T3 (no)
PT (1) PT2086940E (no)
RS (1) RS52408B (no)
SI (1) SI2086940T1 (no)
TW (1) TWI417098B (no)
UA (1) UA97813C2 (no)
UY (1) UY30762A1 (no)
WO (1) WO2008068231A1 (no)
ZA (1) ZA200903907B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
PL3250182T3 (pl) * 2015-01-27 2023-07-31 Janssen Pharmaceutica Nv Kompozycje dyspergowalne
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
US10196360B2 (en) * 2015-10-20 2019-02-05 Zhejiang Hisun Pharmaceutical Co., Ltd. Crystal forms of bedaquiline fumarate and preparation methods therefor
ES2984746T3 (es) * 2016-07-20 2024-10-30 Novartis Ag Derivados de aminopiridina y su uso como inhibidores selectivos de ALK-2
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
JP7102500B2 (ja) 2017-07-14 2022-07-19 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
JP7654544B2 (ja) * 2018-12-13 2025-04-01 マンカインド コーポレイション ベダキリンの組成物、それらを含む組み合わせ、それらを調製するための方法、それらを含む使用及び治療方法
CN113271930A (zh) 2019-01-09 2021-08-17 詹森药业有限公司 治疗非结核分枝杆菌疾病的组合
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
EP4243800A1 (en) 2020-11-12 2023-09-20 JANSSEN Pharmaceutica NV Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) * 2022-07-07 2025-06-24 上海交通大学 含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
WO1998018326A1 (en) 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
CZ300261B6 (cs) * 1996-10-30 2009-04-01 Eli Lilly And Company Použití hydrochloridové soli raloxifenu pro prípravu léciva pro prevenci rakoviny prsu
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
BRPI0312927B8 (pt) * 2002-07-25 2021-05-25 Janssen Pharmaceutica Nv "compostos, derivados de quinolina, composição, seu uso como inibidores micobacteriais, bem como processo para preparação dos referidos derivados".
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CN1976704B (zh) * 2004-05-28 2012-12-05 詹森药业有限公司 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
AP2487A (en) * 2004-09-02 2012-10-03 Janssen Pharmaceutica Nv Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
KR101301573B1 (ko) * 2004-12-24 2013-09-04 얀센 파마슈티카 엔.브이. 잠재성 튜버큐로시스의 치료법

Also Published As

Publication number Publication date
JP2015028049A (ja) 2015-02-12
HK1214513A1 (zh) 2016-07-29
PL2086940T3 (pl) 2012-10-31
AP2009004870A0 (en) 2009-06-30
SI2086940T1 (sl) 2012-09-28
CL2007003472A1 (es) 2008-08-22
AU2007328945B2 (en) 2014-04-03
PE20081350A1 (es) 2008-09-18
CA2668512C (en) 2015-03-24
ES2387923T3 (es) 2012-10-04
CN105012303A (zh) 2015-11-04
DK2086940T3 (da) 2012-08-20
CA2668512A1 (en) 2008-06-12
AR064149A1 (es) 2009-03-18
US20100028428A1 (en) 2010-02-04
ZA200903907B (en) 2013-08-28
JP5894239B2 (ja) 2016-03-23
CY1113594T1 (el) 2016-06-22
TW200838527A (en) 2008-10-01
KR101514700B1 (ko) 2015-04-24
AP2498A (en) 2012-10-19
UA97813C2 (uk) 2012-03-26
EP2086940B1 (en) 2012-05-16
RS52408B (sr) 2013-02-28
EA017091B1 (ru) 2012-09-28
TWI417098B (zh) 2013-12-01
ME01456B (me) 2014-04-20
KR20090087020A (ko) 2009-08-14
MY148844A (en) 2013-06-14
AU2007328945A1 (en) 2008-06-12
PT2086940E (pt) 2012-08-09
IL199077A (en) 2016-09-29
WO2008068231A1 (en) 2008-06-12
JO2973B1 (en) 2016-03-15
EP2086940A1 (en) 2009-08-12
HRP20120639T1 (hr) 2012-08-31
NO342773B1 (no) 2018-08-06
US8546428B2 (en) 2013-10-01
NZ576485A (en) 2012-01-12
JP2010511663A (ja) 2010-04-15
MX2009005909A (es) 2009-06-16
UY30762A1 (es) 2008-07-03
CN101547904A (zh) 2009-09-30
EA017091B9 (ru) 2014-10-30
BRPI0719693A2 (pt) 2013-12-24
EA200970532A1 (ru) 2009-10-30

Similar Documents

Publication Publication Date Title
NO20092535L (no) Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol
NO20090628L (no) Pyridizinon derivativater
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
NO20081844L (no) Terapeutiske forbindelser
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
UY30779A1 (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
NO20084852L (no) MGLUR5 modulatorer V
ATE520668T1 (de) Sigmarezeptor-inhibitoren
MY164864A (en) Indenone derivative and pharmaceutical composition comprising same
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
MX2023014946A (es) Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal.
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
EA201290229A1 (ru) Производные спиролактама и их применение
GEP20135998B (en) Heterocyclic sulfonamide derivatives
NO20073702L (no) Ikke-steroid glukocorticoid reseptor modulatorer
CO6290762A2 (es) Nuevos derivados quinazolin-2, 4-diona y una composicion farmaceutica para prevenir a tratar la enfermedad neurocerebral
UY29264A1 (es) Tiazolidinonas metasustituidas, su preparación y su uso como medicamento
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
NO20076037L (no) Nye tiazolidinoner uten basisk nitrogen, deres fremstilling og anvendelse som farmasoytiske midler
DE602007004348D1 (de) Arzneimittel zur behandlung von sarkoglykanopathien